智通财经网·2026-01-14 02:35Core Viewpoint - Alibaba Health (00241) has seen its stock price increase by over 30% this month, with a current price of 6.86 HKD and a trading volume of 613 million HKD, following the announcement of a groundbreaking treatment for infantile hemangiomas [1] Group 1: Product Launch - On January 13, Alibaba Health exclusively launched a new drug, Malate Timolol Gel (brand name: Beimeijing®), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. over a period of twelve years [1] - This drug is the first and only topical gel approved for the treatment of "proliferative superficial infantile hemangiomas," marking a significant advancement for China in this medical field [1] Group 2: Regulatory Approval and Market Impact - The drug received approval from the National Medical Products Administration (NMPA) for market release by September 30, 2025, indicating a shift from following to leading in this therapeutic area [1] - Beimeijing® has also been recognized by the national drug pricing management system, receiving the first overseas drug price certificate, which establishes a traceable and referenceable price benchmark for Chinese original research drugs in the international market [1] - This new pricing mechanism addresses the gap in international certification for Chinese pharmaceutical products and provides a more standardized and transparent value support for global cooperation, registration, and payment negotiations for innovative drugs [1]